Myelodysplastic Syndrome - Pipeline Review, H1 2018
Myelodysplastic Syndrome - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 69, 51, 3, 19 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 8, 9, 3, 2 and 2 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
4SC AG
AbbVie Inc
Acceleron Pharma Inc
Actinium Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Altor BioScience Corp
Amgen Inc
Angiocrine Bioscience Inc
Apogenix AG
Aprea AB
Aptevo Therapeutics Inc
arGEN-X BV
Array BioPharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Path Holdings Inc
BioLineRx Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cantex Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
Cellectis SA
Cellerant Therapeutics Inc
Celyad SA
CrystalGenomics Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals LLC
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Forma Therapeutics Inc
Formation Biologics Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corporation
Gadeta BV
Gamida Cell Ltd
GlaxoSmithKline Plc
H3 Biomedicine Inc
Humanigen Inc
IGF Oncology LLC
Imago BioSciences Inc
Immune System Key Ltd
Incyte Corp
Io Therapeutics Inc
Jazz Pharmaceuticals Plc
Johnson & Johnson
JW Pharmaceutical Corp
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kyowa Hakko Kirin Co Ltd
La Jolla Pharmaceutical Company
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Mateon Therapeutics Inc
MediGene AG
MedImmune LLC
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Merus NV
Millennium Pharmaceuticals Inc
NantKwest Inc
Nippon Shinyaku Co Ltd
Nohla Therapeutics Inc
Novartis AG
Onconova Therapeutics Inc
OncoTherapy Science Inc
Opsona Therapeutics Ltd
Oxstem Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Protagonist Therapeutics Inc
Rafael Pharmaceuticals Inc
Sanofi
Silence Therapeutics Plc
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Takara Bio Inc
Teva Pharmaceutical Industries Ltd
Tolero Pharmaceuticals Inc
Trethera Corp
Trillium Therapeutics Inc
VasGene Therapeutics Inc
2
Introduction 8
Myelodysplastic Syndrome - Overview 9
Myelodysplastic Syndrome - Therapeutics Development 10
Myelodysplastic Syndrome - Therapeutics Assessment 32
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 50
Myelodysplastic Syndrome - Drug Profiles 97
Myelodysplastic Syndrome - Dormant Projects 967
Myelodysplastic Syndrome - Discontinued Products 973
Myelodysplastic Syndrome - Product Development Milestones 975
Appendix 986List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2018
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H1 2018
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H1 2018
Myelodysplastic Syndrome - Pipeline by Amgen Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H1 2018
Myelodysplastic Syndrome - Pipeline by Aprea AB, H1 2018
Myelodysplastic Syndrome - Pipeline by Aptevo Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by arGEN-X BV, H1 2018
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by AstraZeneca Plc, H1 2018
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Bayer AG, H1 2018
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by BerGenBio ASA, H1 2018
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Co, H1 2018
Myelodysplastic Syndrome - Pipeline by Calithera Biosciences Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Celgene Corp, H1 2018
Myelodysplastic Syndrome - Pipeline by Cell Medica Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Cellectis SA, H1 2018
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Celyad SA, H1 2018
Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H1 2018
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018
Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Co, H1 2018
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Fate Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Forma Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Formation Biologics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Fortress Biotech Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Forty Seven Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Fujifilm Holdings Corporation, H1 2018
Myelodysplastic Syndrome - Pipeline by Gadeta BV, H1 2018
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Humanigen Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H1 2018
Myelodysplastic Syndrome - Pipeline by Imago BioSciences Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Immune System Key Ltd, H1 2018
Myelodysplastic Syndrome - Pipeline by Incyte Corp, H1 2018
Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H1 2018
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H1 2018
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H1 2018
Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H1 2018
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H1 2018
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Research Methodology
The research study released with title "Myelodysplastic Syndrome - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Myelodysplastic Syndrome Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Myelodysplastic Syndrome Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Myelodysplastic Syndrome Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Myelodysplastic Syndrome Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Myelodysplastic Syndrome - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
